Nemera has won the ‘Best New Product’ category at the annual INTERPHEX Awards

International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral Drug Association (PDA), has announced the winners for the INTERPHEX Exhibitor Awards for 2016.

Nemera was recognized for the ‘Best New Product’ for Novelia® BFS, its preservative-free multi-dose eyedropper combined with bottlepack® technology.

Novelia® works with high viscosity suspensions and solutions of up to 1500 cps and limits the distribution of liquids to one drop at a time. The doses of the drops are precise, which assist medication adherence.

Nemera and Rommelag combined their advanced technologies and experiences to create a preservative-free multidose ophthalmic dropper processed by Blow-Fill-Seal (BFS).

Key benefits of Novelia®

  • 100% controlled and safe thanks to its patented PureFlowTM Technology
  • Works with high viscosity suspensions and solutions up to 1500cps
  • User-friendly and intuitive: easy eye targeting thanks to its blue tip feature, as easy to use as any standard eyedropper
  • One drop at a time into the patient’s eye
  • Calibrated drops providing a precise dose for a better treatment adherence 

Key benefits of BFS

  • Advanced aseptic BFS process according to US Pharmacopeia, FDA and GMP Guidelines
  • Highest sterility assurance with BFS Technology
  • Proven and cost-effective production
  • Customized container designs for differentiated products
  • Ergonomic and easy to squeeze bottles

Nemera’s Novelia® BFS was presented at the INTERPHEX opening ceremony, on Tuesday, April 26th. The convention is currently taking place at The Javits Center, New York City, until Thursday 28th April.

To learn more about this technology, visit booth 1636.

For further information or to arrange a meeting with a member of the executive team during the show, please contact Juan Sarmiento at juan.sarmiento@nemera.net

See also

Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

  • Marine Silarbi
  • Product Info
  • English
  • Created 27 Apr 2016
  • Modified 03 May 2016
  • Hits 2287